JPS6247193B2 - - Google Patents

Info

Publication number: JPS6247193B2
Authority: JP; Japan
Prior art keywords: oxide; reduced pressure; under reduced; camptothecin; chloroform
Prior art date: 1981-09-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP13841081A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5839683A (ja

Inventor

Sada Myasaka

Seigo Sawada

Kenichiro Nogata

Masahiko Mutai

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Yakult Honsha Co Ltd

Original Assignee

Yakult Honsha Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-09-04

Filing date

1981-09-04

Publication date

1987-10-06

1981-09-04 Application filed by Yakult Honsha Co Ltd filed Critical Yakult Honsha Co Ltd

1981-09-04 Priority to JP13841081A priority Critical patent/JPS5839683A/ja

1982-09-01 Priority to US06/413,879 priority patent/US4473692A/en

1982-09-02 Priority to CA000410691A priority patent/CA1246576A/en

1982-09-03 Priority to DE8282304649T priority patent/DE3274351D1/de

1982-09-03 Priority to EP82304649A priority patent/EP0074256B1/de

1983-03-08 Publication of JPS5839683A publication Critical patent/JPS5839683A/ja

1984-07-18 Priority to US06/632,039 priority patent/US4545880A/en

1987-10-06 Publication of JPS6247193B2 publication Critical patent/JPS6247193B2/ja

1997-05-14 Priority to BR1100879-2A priority patent/BR1100879A/pt

Status Granted legal-status Critical Current

Links

125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 6
-1 R 3 is not -OH Chemical group 0.000 claims description 2
125000002252 acyl group Chemical group 0.000 claims description 2
125000004423 acyloxy group Chemical group 0.000 claims description 2
125000005042 acyloxymethyl group Chemical group 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
125000003710 aryl alkyl group Chemical group 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
229910052717 sulfur Chemical group 0.000 claims description 2
125000004434 sulfur atom Chemical group 0.000 claims description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 32
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 31
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 22
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 20
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 20
230000015572 biosynthetic process Effects 0.000 description 19
238000003786 synthesis reaction Methods 0.000 description 19
239000011541 reaction mixture Substances 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
229940127093 camptothecin Drugs 0.000 description 14
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 14
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 13
150000001875 compounds Chemical class 0.000 description 12
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 11
229960000583 acetic acid Drugs 0.000 description 11
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
239000005457 ice water Substances 0.000 description 8
238000010898 silica gel chromatography Methods 0.000 description 8
238000003756 stirring Methods 0.000 description 8
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
MYQKIWCVEPUPIL-QFIPXVFZSA-N 7-ethylcamptothecin Chemical compound C1=CC=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 MYQKIWCVEPUPIL-QFIPXVFZSA-N 0.000 description 7
239000013078 crystal Substances 0.000 description 7
QOJFTZYHCMXUHG-FQEVSTJZSA-N (4s)-4-ethyl-4-hydroxy-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione 6-oxide Chemical compound C1=C2C=CC=CC2=[N+]([O-])C2=C1CN(C1=O)C2=CC2=C1COC(=O)[C@]2(O)CC QOJFTZYHCMXUHG-FQEVSTJZSA-N 0.000 description 6
SZTZIXLREYEION-QHCPKHFHSA-N 11-propylcamptothecin Chemical compound C1=CC=C2C(CCC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 SZTZIXLREYEION-QHCPKHFHSA-N 0.000 description 5
NNFHDMYHXQYBDD-UHFFFAOYSA-N 5-methoxycamptothecin Chemical compound C1=CC=C2C=C(C(OC)N3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 NNFHDMYHXQYBDD-UHFFFAOYSA-N 0.000 description 5
150000001204 N-oxides Chemical class 0.000 description 5
229910052943 magnesium sulfate Inorganic materials 0.000 description 5
235000019341 magnesium sulphate Nutrition 0.000 description 5
239000000126 substance Substances 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 4
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 4
239000012141 concentrate Substances 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
HPDRGGNSEBLDKL-NRFANRHFSA-N ac1l3zgz Chemical compound C1=CC=C2C(CO)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HPDRGGNSEBLDKL-NRFANRHFSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000001093 anti-cancer Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
239000002904 solvent Substances 0.000 description 3
FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
229960004926 chlorobutanol Drugs 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
229910015900 BF3 Inorganic materials 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 1
241000759909 Camptotheca Species 0.000 description 1
241000759905 Camptotheca acuminata Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
208000007093 Leukemia L1210 Diseases 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
241001529936 Murinae Species 0.000 description 1
AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000209018 Nyssaceae Species 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
UGJVZXBXVRMUSG-UHFFFAOYSA-K [B+3].[F-].[F-].[F-] Chemical compound [B+3].[F-].[F-].[F-] UGJVZXBXVRMUSG-UHFFFAOYSA-K 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000007336 electrophilic substitution reaction Methods 0.000 description 1
PVBRSNZAOAJRKO-UHFFFAOYSA-N ethyl 2-sulfanylacetate Chemical compound CCOC(=O)CS PVBRSNZAOAJRKO-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
238000000034 method Methods 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
238000001668 nucleic acid synthesis Methods 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
238000001226 reprecipitation Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
239000013076 target substance Substances 0.000 description 1

Landscapes

Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP13841081A 1981-09-04 1981-09-04 新規なカンプトテシン誘導体 Granted JPS5839683A (ja)

Priority Applications (7)

Application Number	Priority Date	Filing Date	Title
JP13841081A JPS5839683A (ja)	1981-09-04	1981-09-04	新規なカンプトテシン誘導体
US06/413,879 US4473692A (en)	1981-09-04	1982-09-01	Camptothecin derivatives and process for preparing same
CA000410691A CA1246576A (en)	1981-09-04	1982-09-02	Camptothecin derivatives and process for preparing same
DE8282304649T DE3274351D1 (en)	1981-09-04	1982-09-03	Camptothecin derivatives, processes for preparing same, formulations containing such derivatives and their use
EP82304649A EP0074256B1 (de)	1981-09-04	1982-09-03	Camptothecine Derivate, Verfahren zu ihrer Herstellung, Zusammensetzungen welche diese Derivate enthalten und ihre Anwendung
US06/632,039 US4545880A (en)	1981-09-04	1984-07-18	Photochemical process for preparing camptothecin derivatives
BR1100879-2A BR1100879A (pt)	1981-09-04	1997-05-14	Novos derivados de camptotecina

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP13841081A JPS5839683A (ja)	1981-09-04	1981-09-04	新規なカンプトテシン誘導体

Publications (2)

Publication Number	Publication Date
JPS5839683A JPS5839683A (ja)	1983-03-08
JPS6247193B2 true JPS6247193B2 (de)	1987-10-06

Family

ID=15221303

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP13841081A Granted JPS5839683A (ja)	1981-09-04	1981-09-04	新規なカンプトテシン誘導体

Country Status (2)

Country	Link
JP (1)	JPS5839683A (de)
BR (1)	BR1100879A (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04137596A (ja) *	1990-09-27	1992-05-12	Shimadzu Corp	制御システムのカード誤挿入防止機構
US8476438B2 (en)	2006-04-27	2013-07-02	Kabushiki Kaisha Yakult Honsha	Process for production of camptothecin derivative

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0615546B2 (ja) *	1986-02-24	1994-03-02	株式会社ヤクルト本社	新規なカンプトテシン誘導体
JPH0615547B2 (ja) *	1988-01-20	1994-03-02	株式会社ヤクルト本社	新規なカンプトテシン誘導体
US6177439B1 (en)	1995-06-06	2001-01-23	Reddy's Research Foundation	Water soluble analogues of 20(S)-camptothecin
US6214836B1 (en)	1995-06-06	2001-04-10	Dr. Reddy's Research Foundation	Water soluble analogues of 20(S)-camptothecin
US7495099B2 (en) *	2002-10-31	2009-02-24	Nippon Kayaku Kabushiki Kaisha	High-molecular weight derivatives of camptothecins
US7067666B2 (en) *	2003-06-27	2006-06-27	Research Triangle Institute	7-substituted camptothecin and camptothecin analogs and methods for producing the same
WO2006038526A1 (ja)	2004-10-01	2006-04-13	Kabushiki Kaisha Yakult Honsha	イリノテカン酸付加塩
WO2009002489A2 (en) *	2007-06-25	2008-12-31	Scinopharm Taiwan Ltd.	Crystalline polymorph of 7-ethyl-10-hydroxycamptothecin

1981
- 1981-09-04 JP JP13841081A patent/JPS5839683A/ja active Granted
1997
- 1997-05-14 BR BR1100879-2A patent/BR1100879A/pt active IP Right Grant

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04137596A (ja) *	1990-09-27	1992-05-12	Shimadzu Corp	制御システムのカード誤挿入防止機構
US8476438B2 (en)	2006-04-27	2013-07-02	Kabushiki Kaisha Yakult Honsha	Process for production of camptothecin derivative

Also Published As

Publication number	Publication date
BR1100879A (pt)	2000-03-14
JPS5839683A (ja)	1983-03-08

Publication	Publication Date	Title
EP0074256B1 (de)	1986-11-20	Camptothecine Derivate, Verfahren zu ihrer Herstellung, Zusammensetzungen welche diese Derivate enthalten und ihre Anwendung
USRE32518E (en)	1987-10-13	Camptothecin derivatives
KR100516593B1 (ko)	2005-09-22	고 친유성 캠프토테신 유도체
JPS6247195B2 (de)	1987-10-06
JP5824448B2 (ja)	2015-11-25	モルフィナンおよびモルフィノン化合物の調製法
JPS6232749B2 (de)	1987-07-16
JPH05213936A (ja)	1993-08-24	抗潰瘍剤合成の新規方法
JPH0312070B2 (de)	1991-02-19
JPH0310630B2 (de)	1991-02-14
JPS6247193B2 (de)	1987-10-06
CN111253391A (zh)	2020-06-09	一种含氘氮杂环二酮化合物用于治疗流感
JP5762624B2 (ja)	2015-08-12	安定な７員環ラクトンを含むカンプトテシン化合物、それらの製造方法及び使用
Wang et al.	2018	A novel and practical synthesis of CAT3: a phenanthroindolizidine alkaloid with potential in treating glioblastoma
JP3499246B2 (ja)	2004-02-23	カンプトテシン誘導体の製造法
JPS6247194B2 (de)	1987-10-06
JPS6247873B2 (de)	1987-10-09
JPH029032B2 (de)	1990-02-28
US6187783B1 (en)	2001-02-13	Phenanthridinium derivatives
JP4477510B2 (ja)	2010-06-09	１０−ヒドロキシ−４−（ｓ）カンプトテンシンからトポテカンを調製する方法
JPH07101956A (ja)	1995-04-18	ヒドロキシカンプトテシン化合物の製法
WO2020216034A1 (zh)	2020-10-29	艾日布林的中间体及其合成方法和用途
JPS636072B2 (de)	1988-02-08
JPS6247192B2 (de)	1987-10-06
JPS636070B2 (de)	1988-02-08
JP3857353B2 (ja)	2006-12-13	ピロロキノリン誘導体

JPS6247193B2 - - Google Patents

Info

Links

Landscapes

Priority Applications (7)

Applications Claiming Priority (1)

Publications (2)

Family

ID=15221303

Family Applications (1)

Country Status (2)

Cited By (2)

Families Citing this family (8)

Cited By (2)

Also Published As

Similar Documents